Evaluation of magnesium deficiency

Diseases

Summary

Magnesium deficiency is a state of decreased total body magnesium content. The human body contains 21-28 g of magnesium, the majority of which is localized in bone (>53%) and nonmuscular tissue (approximately 19%). Hypomagnesemia (low serum magnesium concentration) is generally defined as serum magnesium <1.5 mEq/L.[1]

Serum magnesium level is a poor indicator of the total magnesium content and availability in the body, because only 1% of magnesium is found in the extracellular fluid. There is no simple, rapid, and accurate laboratory test to determine total body magnesium status in humans.[2]

Determination of urinary magnesium level provides an indirect assessment of whole body magnesium content, especially when the urinary value is compared with the serum level.[3]

Magnesium deficiency is usually detected because of the resultant hypomagnesemia. However, it may also be revealed by the development of clinical symptoms or associated hypokalemia or hypocalcemia.

Calcium competes with magnesium for uptake in the loop of Henle, and an increase in the filtered calcium load can impair magnesium reabsorption. Hypomagnesemia, in turn, leads to parathyroid hormone (PTH) resistance and a decrease in PTH secretion, both of which lead to hypocalcemia.
Hypokalemia is commonly seen in patients with hypomagnesemia, partly because the associated underlying disorders can produce both these disturbances. However, there is also evidence that hypomagnesemia can lead to increased renal potassium wasting.

Patients with abnormalities of magnesium homeostasis typically fall into one of three groups:

Patients with magnesium deficiency (low total body magnesium content) and a resultant hypomagnesemia (low serum magnesium concentration)
Patients with hypomagnesemia (low serum magnesium concentration) in the absence of magnesium deficiency (i.e., a normal total body magnesium content)
Patients with magnesium deficiency (low total body magnesium content) but no evidence of hypomagnesemia (i.e., a normal serum magnesium concentration).

Magnesium homeostasis

About 60% of magnesium in the serum is free, whereas approximately 33% is bound to proteins, and <7% is bound to citrate, bicarbonate, ATP, and phosphate.[4]

Magnesium status is regulated by the intestines, which control absorption; the kidneys, which control excretion; and bone, which is the major storage site. Absorption and excretion are mediated by the selective magnesium channel TRPM6, whereas magnesium uptake and release from tissues outside the intestines and kidneys is controlled by TRPM7, which has an approximately 60% homology to TRPM6.[5] [6]

Absorption: magnesium absorption is a saturable process that occurs throughout the small and large intestines, with most of the absorption taking place in the colon. The average daily intake of magnesium is approximately 320 mg in men and 240 mg in women; approximately two-thirds of this amount is eliminated with the feces, while one third is absorbed and passed into the circulation.[7] Magnesium regulates the expression of TRPM6; a sustained fall in magnesium level results in increased expression, and increased magnesium absorption.[8] [9]
Excretion and reabsorption: the major site of reabsorption is the loop of Henle, although additional reabsorption takes place in the distal convoluted tubule.[10] Approximately 2400 mg/day of magnesium passes through the kidneys, <5% of which is eventually excreted. Because magnesium regulates the expression of TRPM6, a sustained fall in magnesium level results in increased magnesium reabsorption.[8]
Although there is no direct hormonal control of magnesium absorption, excretion, and reabsorption, TRPM6 expression appears to be under estrogen modulation.

There is normally very little exchange between intracellular and extracellular magnesium. In the acute phase of a fall in magnesium content, intestinal absorption and renal reabsorption both increase. Hormones such as glucagon, catecholamines, and PTH can mobilize magnesium from bone and other tissues.[11] Magnesium, in turn, exhibits negative feedback on catecholamine release. Conversely, hormones such as insulin, antidiuretic hormone (ADH), and thyroid hormone promote magnesium uptake and storage.[11]

Cellular functions of magnesium

Magnesium is a predominantly intracellular ion and is distributed between the nucleus, endoplasmic or sarcoplasmic reticulum, mitochondria, and cytoplasm.[12] Approximately 200 enzymes involved in cellular metabolism and the cell cycle require magnesium as a cofactor, including adenyl cyclase and ATPases. Magnesium is also an important cofactor for potassium and calcium channels, and therefore plays a role in regulating action potentials in cardiac and neural tissues, as well as calcium signaling in a wide range of tissues.[13]

Recommended dietary allowance for magnesium

The recommended dietary allowance for magnesium varies according to age and sex as follows:[1]

Recommended Dietary Allowances (RDAs) for Magnesium

Table used with permission from the U.S. Department of Health and Human Services, National Institutes of Health. Original source for figures: Institute of Medicine (IOM). Food and Nutrition Board. Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC: National Academy Press, 1997.

Library

Recommended Dietary Allowances (RDAs) for Magnesium

Citations

Key Articles

Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003 May;24(2):47-66.[Abstract][Full Text]
Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. 2005 Jan-Feb;20(1):3-17.[Abstract]

Referenced Articles

1. National Institutes of Health. Magnesium: Fact Sheet for Health Professionals. Jun 2022 [internet publication].[Full Text]
2. Franz KB. A functional biological marker is needed for diagnosing magnesium deficiency. J Am Coll Nutr. 2004 Dec;23(6):738S-41S.[Abstract]
3. Costello RB, Nielsen F. Interpreting magnesium status to enhance clinical care: key indicators. Curr Opin Clin Nutr Metab Care. 2017 Nov;20(6):504-11.[Abstract][Full Text]
4. Shils ME. Magnesium. In: Shils ME, Olson JA, Shike M, et al., eds. Modern nutrition in health and disease. 9th ed. New York, NY: Lippincott Williams & Wilkins; 1999:169-192.
5. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002 Jun;31(2):166-70.[Abstract]
6. Nadler MJ, Hermosura MC, Inabe K, et al. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature. 2001 May 31;411(6837):590-5.[Abstract]
7. Wester PO. Magnesium. Am J Clin Nutr. 1987 May;45(5 Suppl):1305-12.[Abstract]
8. Groenestege WM, Hoenderop JG, van den Heuvel L, et al. The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ content and estrogens. J Am Soc Nephrol. 2006 Apr;17(4):1035-43.[Abstract][Full Text]
9. Cao G, Hoenderop JG, Bindels RJ. Insight into the molecular regulation of the epithelial magnesium channel TRPM6. Curr Opin Nephrol Hypertens. 2008 Jul;17(4):373-8.[Abstract]
10. Quamme GA, de Rouffignac C. Epithelial magnesium transport and regulation by the kidney. Front Biosci. 2000 Aug 1;5:D694-711.[Abstract]
11. Romani AM, Scarpa A. Regulation of cellular magnesium. Front Biosci. 2000 Aug 1;5:D720-34.[Abstract]
12. Gunther T. Functional compartmentation of intracellular magnesium. Magnesium. 1986;5(2):53-9.[Abstract]
13. Romani A, Scarpa A. Regulation of cell magnesium. Arch Biochem Biophys. 1992 Oct;298(1):1-12.[Abstract]
14. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003 May;24(2):47-66.[Abstract][Full Text]
15. Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015 Sep 23;7(9):8199-226.[Abstract][Full Text]
16. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf. 2005;28(9):763-88.[Abstract]
17. Liamis G, Hoorn EJ, Florentin M, et al. An overview of diagnosis and management of drug-induced hypomagnesemia. Pharmacol Res Perspect. 2021 Aug;9(4):e00829.[Abstract][Full Text]
18. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008 Aug;69(2):338-41.[Abstract]
19. Lameris AL, Hess MW, van Krujisbergen I, et al. Omeprazole enhances the colonic expression of the Mg2+ transporter TRPM6. Pflugers Arch. 2013 Nov;465(11):1613-20.[Abstract]
20. US Food and Drug Administration. FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). March 2011. [internet publication].[Full Text]
21. Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008 Nov 1;113(9):2512-7.[Abstract]
22. Barton CH, Vaziri ND, Martin DC, et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med. 1987 Oct;83(4):693-9.[Abstract]
23. Romani AM. Magnesium homeostasis and alcohol consumption. Magnes Res. 2008 Dec;21(4):197-204.[Abstract]
24. Ayuk J, Gittoes NJ. Contemporary view of the clinical relevance of magnesium homeostasis. Ann Clin Biochem. 2014 Mar;51(pt 2):179-88.[Abstract][Full Text]
25. Wolf FI, Cittadini AR, Maier JA. Magnesium and tumors: ally or foe? Cancer Treat Rev. 2009 Jun;35(4):378-82.[Abstract]
26. Papazachariou IM, Martinez-Isla A, Efthimiou E, et al. Magnesium deficiency in patients with chronic pancreatitis identified by an intravenous loading test. Clin Chim Acta. 2000 Dec;302(1-2):145-54.[Abstract]
27. Liu M, Yang H, Mao Y. Magnesium and liver disease. Ann Transl Med. 2019 Oct;7(20):578.[Abstract][Full Text]
28. Nadar S, Lip GY, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem. 2003 Sep;40(pt 5):439-52.[Abstract][Full Text]
29. Pironi L, Malucelli E, Guidetti M, et al. The complex relationship between magnesium and serum parathyroid hormone: a study in patients with chronic intestinal failure. Magnes Res. 2009 Mar;22(1):37-43.[Abstract]
30. Disashi T, Iwaoka T, Inoue J, et al. Magnesium metabolism in hyperthyroidism. Endocr J. 1996 Aug;43(4):397-402.[Abstract][Full Text]
31. James MF, Cork RC, Harlen GM, et al. Interactions of adrenaline and magnesium on the cardiovascular system of the baboon. Magnesium. 1988;7(1):37-43.[Abstract]
32. Hampson G, Konrad MA, Scoble J. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol. 2008 Sep 24;9:12.[Abstract][Full Text]
33. Sha Q, Pearson W, Burcea LC, et al. Human FXYD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel. Am J Physiol Renal Physiol. 2008 Jul;295(1):F91-9.[Abstract][Full Text]
34. Nijenhuis T, Vallon V, van der Kemp AW, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005 Jun;115(6):1651-8.[Abstract][Full Text]
35. Naderi AS, Reilly RF Jr. Hereditary etiologies of hypomagnesemia. Nature Clin Pract Nephrol. 2008 Feb;4(2):80-9.[Abstract]
36. Vezzoli G, Soldati L, Gambaro G. Roles of calcium-sensing receptor (CaSR) in renal mineral ion transport. Curr Pharm Biotechnol. 2009 Apr;10(3):302-10.[Abstract]
37. Enaruna NO, Ande A, Okpere EE. Clinical significance of low serum magnesium in pregnant women attending the University of Benin Teaching Hospital. Niger J Clin Pract. 2013 Oct-Dec;16(4):448-53.[Abstract][Full Text]
38. Sukonpan K, Phupong V. Serum calcium and serum magnesium in normal and preeclamptic pregnancy. Arch Gynecol Obstet. 2005 Nov;273(1):12-6.[Abstract]
39. Kisters K, Niedner W, Fafera I, et al. Plasma and intracellular Mg2+ concentrations in pre-eclampsia. J Hypertens. 1990 Apr;8(4):303-6.[Abstract]
40. Martin KJ, González EA, Slatopolsky E. Clinical consequences and management of hypomagnesemia. J Am Soc Nephrol. 2009 Nov;20(11):2291-5.[Abstract][Full Text]
41. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999 Jul;10(7):1616-22.[Abstract][Full Text]
42. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm 2009 Aug;6(8 Suppl):S51-5.[Abstract]
43. Association of British Clinical Diabetologists. Joint British Diabetes Societies 02: the management of diabetic ketoacidosis in adults. Mar 2023 [internet publication].[Full Text]
44. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. 2005 Jan-Feb;20(1):3-17.[Abstract]
45. Rob PM, Dick K, Bley N, et al. Can one really measure magnesium deficiency using the short-term magnesium loading test? J Intern Med. 1999 Oct;246(4):373-8.[Abstract][Full Text]
46. Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024 Mar;119(3):p 419-37.[Full Text]
47. Rompianesi G, Hann A, Komolafe O, et al. Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis. Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD012010.[Abstract][Full Text]
48. Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019 Jun 13;14:27.[Abstract][Full Text]
49. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 suppl 2):e1-15.[Abstract][Full Text]
50. American College of Radiology. ACR appropriateness criteria: acute pancreatitis. 2019 [internet publication].[Full Text]